On October 26th, The Worldwide Network for Innovation in Clinical Education and Research (WNICER) and The Cura Foundation hosted a webinar on Acute and Chronic Cardiovascular Complications of COVID-19. The panelists were Michael E. Farkouh, MD (University of Toronto), Sascha Goonewardena, MD (University of Michigan Medical School), Peter Libby, MD (Harvard Medical School) and Robert S. Rosenson, MD (The Icahn School of Medicine at Mount Sinai). The discussion was moderated by Max Gomez, PhD, Senior Medical Correspondent, CBS2 New York.
View the webinar.
Long-Term Effects of COVID-19 Webinar
What are the long term effects of COVID-19? How will COVID-19 impact patients' health in the future? On October 5th, William Li, MD, President, Medical Director and CEO of The Angiogenesis Foundation and Andrew von Eschenbach, MD, Previous Commissioner of the U.S. Food and Drug Administration and Former Director of the U.S. National Cancer Institute had a fireside chat on the long-term effects of the novel coronavirus on the health and wellbeing of its survivors. The webinar was moderated by Max Gomez, PhD, Senior Medical Correspondent of CBS2 New York and was hosted by WNICER partners The Cura Foundation and The Angiogenesis Foundation.
View the webinar below.
WNICER celebrates the publication of the TAILOR-PCI trial in JAMA
August 25, 2020
WNICER celebrates the publication of the TAILOR-PCI Randomized Clinical Trial results in the Journal of the American Medical Association (JAMA). The trial highlights the potential clinical impact of a personalized strategy to managing antiplatelet therapy post PCI.
We would like to congratulate and thank WNICER members Drs. Naveen L. Pereira, Michael E. Farkouh, Derek So, Verghese Mathew, Shaun G. Goodman, Mandeep Sidhu, Jean-Francois Tanguay, Yves Rosenberg and other colleagues for their tireless efforts towards advancing science.
Question: Does CYP2C19 genotype–guided prescription of oral P2Y12 inhibitor therapy after percutaneous coronary intervention (PCI) improve ischemic outcomes in patients with acute coronary syndromes and stable coronary artery disease?
Findings: In this randomized clinical trial that included 5302 patients undergoing PCI and included 1849 patients with CYP2C19 loss-of-function alleles in the primary analysis, genotype-guided selection of oral P2Y12 inhibitor therapy, compared with conventional therapy using clopidogrel, resulted in no significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, or severe recurrent ischemia at 12 months (4.0% vs 5.9%, respectively; hazard ratio, 0.66).
Meaning: Among patients with CYP2C19 loss-of-function alleles who underwent PCI, genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy, did not significantly reduce ischemic events based on the treatment effect that the study was powered to detect at 12 months.
Click here to read the full article.
Click here to read the editorial.
DR. VERGHESE MATHEW'S WNICER APPOINTMENT
Mr. John Brooks, CEO of the Worldwide Network for Innovation in Clinical Education and Research (WNICER) is pleased to announce that Dr. Verghese Mathew will assume the role of Director of the Cardiovascular Investigator Program at the WNICER effective Monday, December 16, 2019.
Dr. Mathew is a Professor of Medicine at Loyola University Chicago Stritch School of Medicine. He has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016, holding a number of leadership positions in the cardiac and vascular arenas, with joint appointments in the departments of medicine, cardiology, and radiology; he was recruited to Loyola University Medical Center in 2016 to lead the division of cardiology.
Dr. Mathew has done extensive work in the field of interventional cardiology including complex CAD, peripheral arterial interventions, and TAVR- with both basic and translational research programs. He has been an investigator in many trials that have evaluated and led to the approval of currently utilized technologies, such as coronary stents/drug eluting stents and transcatheter aortic valve replacement (TAVR); as well as phase II-IV pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions. He has published extensively in the field of interventional cardiology.
Dr. Mathew has a keen interest in integrated models of care, focusing on the appropriate application of advanced cardiovascular therapies to complex patient subsets. He continues to be an invited speaker at many national and international cardiovascular scientific conferences.
Dr. Mathew is board certified in interventional cardiology and cardiovascular diseases. He is a Fellow of the American College of Cardiology and a Fellow of the Society for Cardiovascular Angiography and Interventions.